Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

Hao Wu, Eduardo Esteve, Valentina Tremaroli et al. · Nature Medicine · 2017 · 1.6K citations

Life Sciences, Microbiology, Pharmacology +16

Gut microbiota and intestinal FXR mediate the clinical benefits of metformin

Lulu Sun, Cen Xie, Guang Wang et al. · Nature Medicine · 2018 · 1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +13

Mitochondria Bound to Lipid Droplets Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion

Ilan Y. Benador, Michaela Veliova, Kiana Mahdaviani et al. · Cell Metabolism · 2018 · 598 citations · Full text

Life Sciences, Biochemistry, Cell Biology +16

Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model

Guillaume Vial, Marie‐Agnès Chauvin, Nadia Bendridi et al. · Diabetes · 2014 · 190 citations

Life Sciences, Nutritional Sciences, Pharmacology +17

Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients

Valdis Pīrāgs, Harold E. Lebovitz, Pascale Fouqueray · Diabetes Obesity and Metabolism · 2012 · 118 citations

Medicine, Pharmacology, Pharmacotherapy +17